FDA lifts clinical hold on AstraZeneca cancer drug studies

The Food and Drug Administration has lifted a partial clinical hold it placed last month on the enrollment of new patients in a late-stage studies AstraZeneca was conducting on new treatments for head and neck cancer. The clinical trials were for durvalumab as a monotherapy and in combination with tremelimumab, an experimental immuno-oncology drug also in AstraZeneca’s pipeline, for treating head and neck squamous cell carcinoma. The FDA placed a partial clinical hold on the trials in late October…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news